ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2015
Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design.
Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 70 citations in OpenAlex.
- Staging and imaging-based prognostication in renal cell carcinoma: current guidelines and practical considerations.Abdominal radiology (New York) · 2026Review
- Multimodality staging of renal cell carcinoma-pearls & pitfalls.Abdominal radiology (New York) · 2026Review
- The performance ofScientific reports · 2026Article
- Modified OPTIModel with oligometastatic disease for the prediction of overall survival of patients with renal cell cancer and symptomatic long bone metastases.Journal of bone oncology · 2025Article
- Trials Methodology Research: what is it and why should India invest in it?The Lancet regional health. Southeast Asia · 2024Review
- Adaptive clinical trials in surgery: A scoping review of methodological and reporting quality.PloS one · 2024Article
- Bone metastasis screening strategies in urological malignancies: jades from other hills.World journal of urology · 2023Article
- Targeted Molecular Imaging as a Biomarker in Urologic Oncology.The Urologic clinics of North America · 2023Review
- Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials.British journal of cancer · 2022Article
- [Imaging of oligometastatic disease in selected urologic cancers].Der Urologe. Ausg. A · 2021Review
- Article
- Practical considerations for quantitative clinical SPECT/CT imaging of alpha particle emitting radioisotopes.Theranostics · 2021Article
- Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.Current urology reports · 2019Review
- When to keep it simple - adaptive designs are not always useful.BMC medicine · 2019Article
- PET imaging in renal cancer.Current opinion in oncology · 2019Review
- Article
- Imaging Advances in the Management of Kidney Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Review
- An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma.Nature reviews. Urology · 2018Review
- Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2018Article
- The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundThe detection of occult bone metastases is a key factor in determining the management of patients with renal cell carcinoma (RCC), especially when curative surgery is considered. This prospective study assessed the sensitivity of (18)F-labelled sodium fluoride in conjunction with positron emission tomography/computed tomography ((18)F-NaF PET/CT) for detecting RCC bone metastases, compared with conventional imaging by bone scintigraphy or CT. PATIENTS AND
methodsAn adaptive two-stage trial design was utilized, which was stopped after the first stage due to statistical efficacy. Ten patients with stage IV RCC and bone metastases were imaged with (18)F-NaF PET/CT and (99m)Tc-labelled methylene diphosphonate ((99m)Tc-MDP) bone scintigraphy including pelvic single photon emission computed tomography (SPECT). Images were reported independently by experienced radiologists and nuclear medicine physicians using a 5-point scoring system.
resultsSeventy-seven lesions were diagnosed as malignant: 100% were identified by (18)F-NaF PET/CT, 46% by CT and 29% by bone scintigraphy/SPECT. Standard-of-care imaging with CT and bone scintigraphy identified 65% of the metastases reported by (18)F-NaF PET/CT. On an individual patient basis, (18)F-NaF PET/CT detected more RCC metastases than (99m)Tc-MDP bone scintigraphy/SPECT or CT alone (P = 0.007). The metabolic volumes, mean and maximum standardized uptake values (SUV mean and SUV max) of the malignant lesions were significantly greater than those of the benign lesions (P < 0.001).
conclusions(18)F-NaF PET/CT is significantly more sensitive at detecting RCC skeletal metastases than conventional bone scintigraphy or CT. The detection of occult bone metastases could greatly alter patient management, particularly in the context when standard-of-care imaging is negative for skeletal metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.